Please Find enclosed unaudited statement as on 30th June 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tejnaksh Healthcare has filed its unaudited Q1 FY26 results for the quarter ended June 30, 2025, along with a clean limited review report from Maheshwari & Co. Standalone revenue from operations fell sharply to ₹178.06 lakhs from ₹240.43 lakhs in the same quarter last year, a drop of about 26%. Standalone profit after tax also more than halved to ₹33.73 lakhs from ₹75.35 lakhs year-on-year. On a consolidated basis, revenue declined to ₹263.97 lakhs from ₹312.39 lakhs (around 15% lower), while consolidated profit after tax fell to ₹21.27 lakhs from ₹59.87 lakhs (a roughly 64% drop). EPS on a standalone basis slipped to ₹0.17 from ₹0.37. The company continues to operate in a single segment — Medical and Healthcare Services — and the auditor flagged no modifications or concerns in its review.
Weak quarter for Tejnaksh Healthcare with sharp year-on-year declines in both revenue and profit across standalone and consolidated numbers. This is likely to weigh negatively on short-term investor sentiment, though the clean auditor review and continued profitability offer some reassurance.